Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Referral Count:
3
Story being shared
Baylor institute licenses compound to Ultragenyx
Ultragenyx Pharmaceutical secured exclusive North American rights to triheptanoin, a synthetic compound designed to treat long-chain fatty acid oxidation disorders, from the Baylor Research Institute based in Dallas. Ultragenyx has the option to license worldwide rights for the drug.
Or we can send an email on your behalf